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arc Vanderheyden, MD
alst, Belgium
ongestive heart failure (HF) is associated with electrical
nd conduction abnormalities. Aside from the higher risk
or sudden cardiac death, patients often present with atrial
brillation (AF) and left ventricular (LV) conduction ab-
ormalities. The prevalence of atrial fibrillation increases
ith the severity of heart failure and worsens its course by
oss of atrial contraction, poor rate control, and irregular
hythm. Cardiac resynchronization therapy (CRT) im-
roves symptoms and exercise tolerance in patients with
ongestive heart failure and cardiac dyssynchrony. These
ffects are paralleled by reverse LV remodeling, improve LV
unction, and translate into an improved prognosis on top of
he optimal medical treatment (1). Clinical benefits are
onsistent across the multiple studies, and the therapy has
volved into the class I indication for HF patients with a
road QRS complex, severely depressed LV function, and
inus rhythm (2).
See page 1239
In this issue of the Journal, Upadhyay et al. (3) bring to
ur attention CRT in HF patients with permanent AF. In
meta-analysis of 5 cohort studies, they found slightly
reater improvement in LV ejection fraction but a smaller
unctional benefit measured from exercise tolerance or
uality of life in these patients compared with patients with
inus rhythm. However, the meta-analysis included obser-
ational studies in the absence of sufficiently powered
andomized trials. The only randomized data available were
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iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ospital, Aalst, Belgium. This work was supported by the Meijer Lavino Foundation
or Cardiac Research.rom the subpopulation of the MUSTIC (MUltisite
Timulation In Cardiomyopathies) trial (4), which was a
rossover study with rather small numbers, significant drop-
uts, and changes in the mode of pacing. In general, the
eta-analysis of observational studies is rather unusual, and
resented studies used surrogate end points of reverse LV
emodeling and function. Therefore, it is encouraging that
he meta-analysis is corroborated by 2 recent studies (5,6).
lthough still being nonrandomized, they included a rela-
ively large number of patients and reported long-term
linical follow-up with mortality as the primary end point.
n both studies, Khadjooi et al. (5) and the report of the
ILOS (Multicentre Longitudinal Observational Study)
roup (6) showed that CRT led to a similar benefit in CRT
andidates with AF compared with patients with sinus
hythm. Thus, we can agree with Upadhyay et al. (3) that
he analysis of the existing observational data is timely and
ay serve as a hypothesis-generating effort relevant for the
esign of the future randomized trials.
What should be addressed in these trials? The resynchro-
ization with consistent biventricular capture, the prerequi-
ite for the CRT benefit (7), is often difficult to achieve
ecause of irregularity and intermittent fast ventricular rates
n AF. It is controversial whether optimal medical rate
ontrol should be achieved pharmacologically or nonphar-
acologically by ablation of the atrioventricular junction
AVJ). Studies with the pharmacological strategy of rate
ontrol suggested that when adequate CRT delivery can be
chieved with rates of biventricular pacing (BVP) of approx-
mately 85% to 90%, the benefits are comparable to patients
ith sinus rhythm (5,4,8). In case of inadequate rates of
VP 85%, nonpharmacological AVJ ablation has been
dvocated (6,9). It ensures that CRT is correctly delivered
ithout fusion or pseudofusion, eliminates the risk of
ncontrolled ventricular rate, and regularizes the heart rate,
ll effects that might be particularly beneficial in patients
resenting with HF and AF (10,11). The “ablate and CRT”
trategy was also applied prospectively in the previously
entioned multicenter MILOS study (6) and resulted in a
trikingly superior impact on survival compared with pa-
ients with the optimal medical rate control. This supports
he initiation of a prospective randomized trial to test the
ostulate that AVJ ablation is a fundamental adjunct to
nsure adequate CRT delivery. However, the poor survival
n patients with medical rate control despite adequate BVP
apture is at odds with earlier studies reporting a beneficial
utcome on surrogate end points (4,5,8). It should be
ointed out that in the MILOS study (6), the decision to
blate was already performed at 2 months after CRT
mplantation. Although the decision seems to be justified on
he basis of inadequate BVP capture, no information is
rovided on the CRT effect on LV remodeling and doses or
ombinations of negative chronotropic drugs. Multiple drug
egimens are frequent in these patients, and homogeneity
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Resynchronization in HF With AF October 7, 2008:1247–9nd optimization of the medical therapy should be critically
eviewed in the trials.
Nevertheless, the rapid translation from the suboptimal
ate control to ablate and pace strategy may be justified by
he withdrawal of negative chronotropic drugs. It is note-
orthy that digoxin and amiodarone were discontinued in
he ablative arm (6,9), and differences in the medical
egimen might have impacted the survival, possibly by
educing the pro-arrhythmic risks (12).
Atrioventricular junction ablation is considered safe, but
ne should keep in mind the potential adverse effects. Given
he sizable proportion of nonresponders to CRT, one could
onder whether it is acceptable to ablate all patients with
F and make them pacemaker dependent for the rest of
heir lives. Likewise, a small but significant risk of higher
ortality exists if patients are paced at lower heart rates
13), and higher pacing rates in the initial period after AVJ
blation should be considered. Recently, catheter ablative
echniques with either pulmonary vein isolation or the more
xtensive maze-like procedure and targeted ablation of areas
ith low-amplitude potentials in HF patients with par-
xysmal or symptomatic AF have emerged as an effective
reating strategy (14–16). Although the therapy is now
apidly adopted in clinical practice and may be attractive
o consider as an alternative to the conventional AVJ
blation, long-term survival data are lacking. A properly
owered randomized study should ascertain the merits of
RT in HF patients with AF treated either pharmaco-
ogically, by AVJ, or by catheter ablation strategy.
It is interesting that the rates of nonresponders in patients
ith AF are similar to those in patients with sinus rhythm.
he reasons for lack of response are multifactorial. One
actor is the selection of CRT candidates. The use of QRS
uration as inclusion criteria outperformed various tissue
oppler imaging indexes in the recent PROSPECT (Pre-
ictors of Response to CRT) trial (17). However, this trial
id not consider the impact of interventricular dyssynchrony
n combination with the intraventricular delay. Although
ophisticated echocardiographic parameters may be difficult
o assess at an irregular heart rate, the incorporation of this
arameter for identification of the responders could be
elpful (18).
In addition, a prospective algorithm aimed at optimiza-
ion of the CRT programming in nonresponders should be
ncorporated in future trials. A V-V interval adaptation
hould be considered at regular follow-up intervals (19,20).
iven the rate dependency of the optimal V-V interval (20),
he development of a rate-adaptive V-V interval algorithm
n patients with AF is desired. Finally, the design of the
tudies should consider such factors as location of scar in
atients with ischemic etiology, consistency in the lead
osition, concomitant mitral valve regurgitation, and dura-
ion of AF, as well as extracardiac causes of AF. In analogy
o the relationship between the atrial tissue remodeling and
F (21), future studies should also address whether thera-eutic response after CRT may be related to the remodeling
t the molecular level (22,23).
In summary, what should we as clinicians do today in
atients with congestive heart failure presenting with AF
nd broad QRS? The 2007 European Society of Cardiology
uidelines for Cardiac Pacing and CRT have assigned a
lass IIA and level C indication for CRT in such patients
ho have an indication for AVJ ablation (1). Before that is
onsidered, most important is the maximal effort to restore
he sinus rhythm. Recompensation, control of extracardiac
auses of AF, and an attempt for cardioversion under an
ppropriate drug regimen are the primary goals for the
reating cardiologist. The CRT can be considered after
ptimal rate control if cardioversion has failed. The decision
o “ablate and CRT” remains individual and depends on the
areful risk–benefit considerations, including patient age
nd comorbidity, as well as access and experience with
blative techniques including the transseptal catheter-based
pproach. For the time being, the AVJ ablation should be
onsidered in patients with documented poor biventricular
apture despite optimal medical rate control.
eprint requests and correspondence: Dr. Jozef Bartunek, Car-
iovascular Center, OLV Hospital, Moorselbaan 164, 9300 Aalst,
elgium. E-mail: Jozef.Bartunek@olvz-aalst.be.
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